drugset / Trial / NCT01438554
Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma
Phase 1
Completed
89 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Comprehensive Cancer Network · collabNovartis · collab
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to determine the safety and toxicity of the combination of pazopanib and GSK1120212 in patients with solid tumors and identify the maximum tolerated dose (MTD) of this combination for phase II study.
Timeline
- Start
- 2011-10
- Primary completion
- 2016-04
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pazopanib | Small molecule | — | Oral |
| Subject | Trametinib | Small molecule | — | Oral |